Ocular Adverse Effects Linked to Antibody-Drug Conjugates in Cancer Treatment: An In-Depth Analysis - Top-Institutions - MDSpire

Ocular Adverse Effects Linked to Antibody-Drug Conjugates in Cancer Treatment: An In-Depth Analysis

  • By

  • Junxiang Zhou

  • Haoyue Wang

  • Hua Xie

  • Xinyi Xu

  • Hongtao Xiao

  • April 27, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Ophthalmology
    • Pharmacology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Ophthalmology
    • Translational Medicine

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Oncology
    • Pharmacology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Ophthalmology
    • Cancer Pharmacology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Oncology
    • Clinical Pharmacology

Original Source(s)

Ocular Adverse Effects Linked to Antibody-Drug Conjugates in Cancer Treatment: An In-Depth Analysis

  • by Junxiang Zhou, Haoyue Wang, Hua Xie, Xinyi Xu, Hongtao Xiao

  • April 27, 2026

Related Content

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2